Plaque profilings Insights from the Culprit Plaques

Cheol Whan Lee, MD

Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea





Il Big Leafs in CY Medicine Statins and Anti-platelet Agents

HMGCo-A Reductase

P2Y₁₂ Receptor





...the only proven medicine

Landmark Statin Trials

So Luxurious ...

Statin is an anti-atherosclerotic drug.



Rapid Effects of Statin Therapy



Mechanisms of early benefits are not fully understood.



Inside Plaques

Expression of HMG-CoAR in Human Coronary Plaques & Relationship to Plaque Destabilization

Heart 2011;97:715-20

We investigated the expression of HMG-CoAR in coronary atherectomy tissues retrieved from 43 patients with unstable & stable angina, & examined the relationship of HMG-CoAR with plaque instability.




Immunohistochemistry

	Unstable angina (n=22)	Stable angina (n=21)	<i>p-</i> value
α-SM actin (%)	21.4±18.7	33.6±28.7	0.103
CD31 (%)	3.4±4.1	0.3±0.5	0.002
CD68 (%)	10.9±16.2	1.8±1.7	0.016
HMG-CoAR (%)	3.0±4.5	0.4±0.7	0.014


Data are shown as % positive area (immunostaining area/total plaque area×100).




















Relationship Between CD68-Positive Areas & HMG-CoA Reductase-Positive Areas (mm²)







Summary

Statin

HMGCoA Reductase

Liver: cholesterol Plaque: inflammation

PLAQUE STABILIZATION

These findings support a potential role of the HMG-CoAR in the pathogenesis of ACS, and may help explain the early benefits of statin therapy in patients with ACS.





Il Big Leafs in CY Medicine Statins and Anti-platelet Agents


HMGCo-A Reductase

P2Y₁₂ Receptor





Platelet Activation Mechanisms








Cumulative Risk of Stoke, MI or Vascular Death in Patients in the CAPRIE Trial

19,185 patients with atherosclerotic disease






No major safety differences

	Aspırın	Plavix
Any bleed	9.28%	9.27%
ICH	0.49%	0.35%
GI bleed*	2.66%	1.99%

*p<0.05




PLATO: Major Outcomes







Bleeding Tax



"More Bleeding = More Death"

Impact of Bleeding on Mortality after PCI

17,393 patients from REPLACE-2, ACUITY and Horizons



Adjusted Risk for 1-Year Mortality








The PLATO trial: do you believe in magic?

Victor L. Serebruany^{1*} and Dan Atar²



Adenosine Hypothesis?

- vasodilation
- preconditioning
- --immunomodulătion
- -dyspnea
- -heart block
- -renal funtion





Inside Plaques

Differential Expression of P2Y₁₂ Receptor in Culprit Plaques from Patients with AMI & Stable Angina

Am J ardiol 2011 (in press)

We compared the expression of P2Y12 receptors in coronary atherectomy tissues retrieved from 54 patients with AMI (n=35) or stable angina (n=19).



Immunohistochemistry


	AMI (n=35)	Stable angina (n=19)	<i>p-</i> value
α-SM actin (%)	2.9±2.7	12.3±14.4	0.011
CD31 (%)	1.1±1.6	0.2±0.2	0.001
CD68 (%)	15.5±13.6	7.0±14.6	0.038
P2Y12 Receptor (%)	1.1±0.9	0.5±0.4	<0.001

Data are shown as % positive area (immunostaining area/total plaque area×100). AMI: STEMI 27, NSTEMI 8






AMI



Stable angina -




Relationship Between P2Y₁₂Receptor-Positive Areas and CD31 or CD68-Positive Areas (mm²)










Summary



P2Y12 receptor inhibitors may have a dual anti-ischemic effect by inhibiting both platelet activation and plaque destabilization.





Limitations

Specimens were obtained from selected lesions in large vessels because calcified, tortuous, small vessels & those with heavy thrombotic lesions are not suitable for DCA. Thus, our findings may not be applicable to other lesions in AMI patients.

It remains uncertain whether P2Y₁₂R is a cause or consequence of plaque instability. You can see firefighters at every flaming building, but they did not set the blazes!





Thank You!

soupelq gnimud 101 gnixool ...

People start life with clean arteries, live with atherosclerosis and die of acute vascular events.

감사합니다.



